Abstract
Background Abdominal aortic aneurysm (AAA) represents a significant cause of mortality, yet no medical therapies have proven efficacious. The aim of the current study was to leverage human genetic evidence to inform clinical development of interleukin-6 (IL6) signaling inhibition for treatment of AAA.
Methods We focused on rs2228145, a missense variant in the IL6R gene region whose associations are expressed per additional copy of the C allele, corresponding to the genetically-predicted effect of IL6 signaling inhibition. We consider genetic associations with AAA risk in the AAAgen consortium (39,221 cases, 1,086,107 controls) and UK Biobank (2215 cases, 365,428 controls). To validate against known effects of IL6 signaling inhibition, we present associations with rheumatoid arthritis, polymyalgia rheumatica, and severe COVID-19. To explore mechanism specificity, we present associations with thoracic aortic aneurysm, intracranial aneurysm, and coronary artery disease. We further evaluated associations with measures of the abdominal aorta in UK Biobank, and explored genetic associations in clinically-relevant subgroups of the population.
Results We observed strong genetic associations with AAA risk in the AAAgen consortium and in UK Biobank: odds ratio (OR) 0.91 (95% confidence interval [CI]: 0.90 to 0.92, p = 4×10-30) and OR 0.90 (95% CI: 0.84, 0.96, p=0.0007), respectively. The association with AAA risk in UK Biobank was linear in the number of minor alleles: OR 0.91 (95% CI: 0.83, 1.00) in heterozygotes and OR 0.80 (95% CI: 0.71, 0.92) in minor homozygotes. The association was similar for fatal AAA, but with greater uncertainty due to the lower number of events. The association with AAA was of greater magnitude than associations with coronary artery disease and even rheumatologic disorders for which IL6 inhibitors have been approved. No strong associations were observed with thoracic aortic aneurysm, intracranial aneurysm, or abdominal aorta diameter in the general population without AAA. Associations attenuated towards the null in populations with concomitant inflammatory or connective tissue disease.
Conclusions This drug target Mendelian randomization study supports that IL6 signaling inhibition will be efficacious for treating AAA, but not other types of aneurysmal disease. These findings serve to help inform clinical development of IL6 signaling inhibition for AAA treatment.
Competing Interest Statement
SB, HTC and DG are employees of Sequoia Genetics, and were supported by Tourmaline Bio to undertake this work. YC and ED are employees and shareholder of Tourmaline Bio.
Funding Statement
This work was supported by Tourmaline Bio.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research has been conducted using the UK Biobank Resource under Application Number 7439. The authors acknowledge participants and investigators of the UK Biobank and the other cohort studies incorporated in our work. We thank the cohorts and consortia that made their summary-level data publicly available. Data sources are cited throughout this manuscript. Downloads were performed through the following repositories: IL6, https://www.ebi.ac.uk/gwas/studies/GCST90012005; CRP, https://www.ebi.ac.uk/gwas/studies/GCST90029070; AAA, https://csg.sph.umich.edu/willer/public/AAAgen2023/; Rheumatoid arthritis (consortium), https://www.ebi.ac.uk/gwas/studies/GCST90132222; Rheumatoid arthritis (FinnGen), https://www.finngen.fi/en/access_results; Polymyalgia rheumatica, https://www.ebi.ac.uk/gwas/studies/GCST90129454; Severe COVID-19, https://www.covid19hg.org/results/r7/; Thoracic aortic aneurysm, https://www.ebi.ac.uk/gwas/studies/GCST90027266; Intracranial aneurysm, https://cd.hugeamp.org/downloads.html; Coronary artery disease, https://www.ebi.ac.uk/gwas/studies/GCST90132315.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Summary statistics used in our analyses can be accessed through the citations provided. Requests to access UK Biobank data can be made by bona fide researchers from any sector. More information can be found at https://www.ukbiobank.ac.uk/enable-your-research. Statistical code for the analyses undertaken in this work are available from the corresponding author upon reasonable request.
